This update covers the latest health sector developments, including Moderna's COVID-19 vaccine review, GSK's asthma drug FDA ...

Trump administration to restrict COVID vaccines to seniors and high-risk groups, pending more data for everyone else.

Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula, targeting the SARS-CoV-2 ...

The U.S. Food and Drug Administration is warning that certain half-shell oysters that are frozen and raw harvested in South ...

An FDA committee on Thursday recommended that COVID-19 vaccines for the 2025-2026 respiratory virus season — which, for the ...

The FDA picked the LP.8.1 Covid strain for the fall vaccines, fueling concerns that the shots may be limited to only the most ...

I'm a clinical academic, which is quite a rare breed of doctor, because what I'm doing, along with other clinical academics, ...

In a major and controversial policy shift, the FDA announced in a New England Journal of Medicine article that updated ...

FDA's new COVID-19 vaccine policy may restrict low-risk individuals' access, pending clinical trials to prove benefits.

The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to ...

Despite the fact that vaccines against COVID have already undergone strict safety reviews and that people continue to die ...

On May 22, an FDA advisory committee unanimously recommended COVID-19 vaccine manufacturers target the JN.1 variant in their formulations.  The Vaccines and Related Biological Products Advisory ...